Levocarnitine is required for normal fat utilization and energy metabolism in mammalian species. It serves to facilitate entry of longchain fatty acids into cellular mitochondria where they can be used during oxidation and energy production. Severe chronic deficiency is generally a result of an inborn genetic defect where levocarnitine utilization is impaired and not the result of dietary insufficiency. Effects seen in levocarnitine deficiency may include hypoglycemia, progressive myasthenia, hepatomegaly, CHF, cardiomegaly, hepatic coma, neurologic disturbances, encephalopathy, hypotonia and lethargy.
Carprofen is labeled (in the USA) for the relief of pain and inflammation in dogs. It may also prove to be of benefit in other species as well, but data is scant to support its safety beyond very short-term use at this time. In Europe, carprofen is reportedly registered for single dose use in cats, but there have been reported problems ( _e.g._, vomiting) with cats receiving more than a single dose. Carprofen is being investigated for antineoplastic effects in dogs and may be a useful adjunctive treatment for some types of tumors with COX-2 overexpression.
劑量數字暫停提供：VetPro 的劑量改依 DRUGAPI 藥物資料庫對外的內容，DRUGAPI 目前不提供可直接計算的劑量。下方列出 DRUGAPI 的審查結論與劑量審查引用的來源；計算機可手動輸入劑量換算。
依出現頻率分組；嚴重副作用獨立列出，臨床上需立即辨識。
15%